Zurcher Kantonalbank Zurich Cantonalbank Buys 55,333 Shares of Amgen Inc. $AMGN

Zurcher Kantonalbank Zurich Cantonalbank increased its position in Amgen Inc. (NASDAQ:AMGN – Free Report) by 20.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 325,687 shares of the medical research company’s stock after buying an additional 55,333 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Amgen were worth $106,601,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in AMGN. Board of the Pension Protection Fund bought a new position in Amgen in the fourth quarter worth approximately $26,000. Olistico Wealth LLC bought a new stake in shares of Amgen during the fourth quarter valued at approximately $33,000. Cloud Capital Management LLC bought a new stake in shares of Amgen during the third quarter valued at approximately $34,000. Saranac Partners Ltd acquired a new position in shares of Amgen during the third quarter worth approximately $37,000. Finally, Holos Integrated Wealth LLC bought a new position in shares of Amgen in the 4th quarter worth $37,000. 76.50% of the stock is owned by institutional investors.

Amgen Stock Performance

NASDAQ AMGN opened at $355.30 on Monday. The company has a debt-to-equity ratio of 5.78, a current ratio of 1.14 and a quick ratio of 0.90. The stock has a market capitalization of $191.75 billion, a price-to-earnings ratio of 24.97, a PEG ratio of 3.71 and a beta of 0.47. Amgen Inc. has a one year low of $261.43 and a one year high of $391.29. The business’s fifty day moving average is $362.91 and its 200-day moving average is $337.97.

Amgen (NASDAQ:AMGN – Get Free Report) last released its earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share for the quarter, beating analysts’ consensus estimates of $4.76 by $0.53. The firm had revenue of $9.87 billion during the quarter, compared to the consensus estimate of $9.46 billion. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The company’s revenue was up 8.6% compared to the same quarter last year. During the same period in the prior year, the firm earned $5.31 EPS. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. Equities research analysts predict that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, June 5th. Shareholders of record on Friday, May 15th will be given a $2.52 dividend. This represents a $10.08 dividend on an annualized basis and a yield of 2.8%. The ex-dividend date of this dividend is Friday, May 15th. Amgen’s dividend payout ratio (DPR) is currently 70.84%.

Analyst Ratings Changes

A number of analysts have commented on the stock. Freedom Capital lowered shares of Amgen from a “strong-buy” rating to a “hold” rating in a research note on Thursday, February 12th. Sanford C. Bernstein cut shares of Amgen from an “outperform” rating to a “market perform” rating and set a $335.00 price objective for the company. in a report on Tuesday, January 20th. Weiss Ratings reissued a “buy (b)” rating on shares of Amgen in a research report on Monday, December 29th. Wall Street Zen upgraded shares of Amgen from a “hold” rating to a “buy” rating in a report on Saturday, April 11th. Finally, Daiwa Securities Group lifted their price target on Amgen from $370.00 to $410.00 and gave the company an “outperform” rating in a research note on Tuesday, February 10th. One research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, thirteen have assigned a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, Amgen currently has an average rating of “Hold” and a consensus price target of $356.24.

View Our Latest Stock Analysis on AMGN

Amgen Profile

(Free Report)

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.

See Also

• Five stocks we like better than Amgen

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN – Free Report).